HDAC9 and synovial sarcoma: As constitutive or drug-induced ERK activation could counteract the cytotoxic effect of HDAC inhibition, we examined the effects of the MEK1 inhibitor trametinib on the ERK-EGR1 cross-talk in SS cells.